3[1]Oreopoulos DG. Peritoneal dialysis in the past 20 years: An excting journey[J]. Peril Dial Int, 1999,19(suppel 3):3-8.
4[2]Kim MJ, Lee SW, Yang HJ. Influence of CAPD on blood pressure using anbulatory blood pressure monitoring[J]. Perit Dial Int, 1999,19(suppl 1):55.
5[3]Besarab M. Recombinant Human erythropoietin: physiology, pathophysiology of anemia in renal failure and economic aspects to dosing[J]. Am J Nephrol, 1990,10(supple 2):2.
6[4]Joseph W, Eschbach MD, Joan C, et al. Correction of the anemia of end-stage renal disease with ricombinant human erythropoietin: Results of a combined phase I and II clinical trial[J]. New Eng J of Med, 1987,8:73-79.
7[5]Horl WH. How to get the best out of r-Hu EPO[J]. Nephron Dial Transplant, 1995,10(supple 2):92.
8[6]Sloand JA, Shelley MA, Erenstone AL, et al. Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies[J]. Perit Dial Int, 1998,18:522-527.
9[7]Ekstrand A, Kala AR, Tevanen R, et al. Why do patients fail on peritoneal dialysis[J]. Pent Dral Int, 1999,19(supple 1):53.
10[8]Viglino G, Salomone M, Gabella P, et al. Pentonitis in PD: 15 years of italian PD study group[J]. Pent Dial Int, 1998,19(supple 1):38.
